:: urbansheep (urbansheep) wrote,
:: urbansheep

  • Music:

Нейростимуляторы для снятия депрессивных состояний

В Everyone In Silico есть небольшой и логичный штрих — когда тебя клинит, ты можешь вызвать настройки своего состояния и аккуратно подкрутить всё куда надо, сократив уровень проявления каких-то эмоций, или напротив, подняв его, если он был недостаточным. И вот, практически обгоняя время, в последней Компьютерре в новостях пишут о том, что консультативный совет по неврологическим устройствам американской FDA (Food & Drug Administration) рекомендовал одобрить применение нейроимплантов, которые изначально применялись для терапии эпилепсии, но в качестве побочного эффекта выяснилось, что этот же механизм стимуляции положительно влияет на настроение пациентов и приближается по эффективности к фармакологическим препаратам.

The Neurological Devices Panel of the Food and Drug Administration (FDA) voted last month to recommend approval of an application by Cyberonics Inc. to market its vagus nerve stimulation (VNS) therapy system for the "adjunctive long-term treatment of chronic or recurrent depression."

По сути препарат является устройством, подобным кардиостимуляторам, с круглосуточной стимуляцией.

VNS therapy for depression has been under investigation for several years with Houston-based Cyberonics leading the way. The Cyberonics VNS system, which is already approved for the treatment of medication-refractory epilepsy, involves implantation of a device that is fundamentally identical to a cardiac pacemaker in the left shoulder. However, instead of threading the device's electrode downward through blood vessels to the heart, the VNS electrode is threaded through the shoulder muscles to the base of the neck, where the electrode is attached to the left vagus nerve. The vagus nerve receives electrical stimulation for 30 seconds, followed by a five-minute rest, then another 30 seconds of stimulation, with the cycle continually running, 24 hours a day, every day.

Patients treated with VNS had an average improvement of 23.4 percent in depression rating scale scores, compared with an 8 percent improvement in the scores of those who did not receive active stimulation.

A large number of secondary outcomes confirmed improvement as well. As measured by the 24-Item Hamilton Depression Rating Scale (HamD-24), 30 percent of patients receiving VNS achieved a response— defined as a 50 percent or greater reduction in the HamD-24 score—and 17 percent achieved a complete response—defined as a final HamD-24 score of 9 or under. Of those not receiving stimulation, only 13 percent achieved a response, and only 7 percent met criteria for a complete response.

The safety and tolerability of the VNS system were documented when the device was approved for epilepsy in 1997. Since that time, more than 22,000 patients have accumulated nearly 56,000 patient-years of experience with the device.

  • Post a new comment


    Comments allowed for friends only

    Anonymous comments are disabled in this journal

    default userpic

    Your reply will be screened

    Your IP address will be recorded